Lung Cancer Europe (LuCE)

www.lungcancereurope.eu

 

Lung Cancer Europe (LuCE)
S

2020 ESMO Update on IO in Advanced NSCLC: Is Atezo + Bev a Potential Option for non-Sq Disease w/ High PD-L1 Expression? Is There a Meaningful 5-Year OS Improvement With Pembro?

By Lung Cancer Europe (LuCE) FEATURING Sanjay Popat
By Lung Cancer Europe (LuCE) FEATURING Sanjay Popat
95 views
November 26, 2020
Courtesy of Lung Cancer Europe (LuCE). The full video can be found here: https://www.lungcancereurope.eu/2020/10/16/luce-webinar-esmo-2020-lung-cancer-highlights/
0 Comments
Login to view comments. Click here to Login
Videos
16:37
Lung Cancer Europe (LuCE)

ASCO 2022 Early Stage NSCLC Updates

Feat. J. Naidoo
12:41
Lung Cancer Europe (LuCE)

Unresectable Stage III NSCLC: Key Findings

Feat. J. Naidoo
21:39
Lung Cancer Europe (LuCE)

Updates on Biomarker Testing and Oncogene-Driven NSCLC

Feat. E. Felip
09:29
Lung Cancer Europe (LuCE)

Early Stage NSCLC: Standard Adjuvant & New Neoadjuvant Approache…

Feat. S. Ekman
07:07
Lung Cancer Europe (LuCE)

Treatment Approaches in Early Stage and Locally Advanced NSCLC: Impa…

Feat. S. Ekman
09:30
Lung Cancer Europe (LuCE)

Metastatic EGFRm NSCLC: Navigating Treatment Options & Overcomin…

Feat. S. Ekman
04:44
Lung Cancer Europe (LuCE)

Considering Targeted Therapy Data for mNSCLC With ALK & KRAS Mut…

Feat. S. Ekman
10:22
Lung Cancer Europe (LuCE)

IO in mNSCLC: Overview of Efficacy Data for Mono and Chemo Combinati…

Feat. S. Ekman
08:15
Lung Cancer Europe (LuCE)

Liquid Biopsy in NSCLC: Potential of Targeted Therapy, CPIs, Biomark…

Feat. R. A. Stahel
06:15
Lung Cancer Europe (LuCE)

Precision Oncology in Metastatic NSCLC: Efficacy Analysis of ALK, RO…

Feat. R. A. Stahel
14:14
Lung Cancer Europe (LuCE)

Stage 4 NSCLC Molecular Testing: Histology for Treatment Allocation,…

Feat. R. A. Stahel
09:34
Lung Cancer Europe (LuCE)

EGFR Mutations in mNSCLC: 1L TKI Inhibitors, Molecular Resistance Me…

Feat. R. A. Stahel
07:27
Lung Cancer Europe (LuCE)

2020 ESMO Update Advanced ALK+ NSCLC: Should We Consider Lorlatinib …

Feat. S. Popat
09:00
Lung Cancer Europe (LuCE)

2020 ESMO Update on Advanced EGFR-Mutated NSCLC: Mobocertinib (TAK-7…

Feat. S. Popat
07:21
Lung Cancer Europe (LuCE)

2020 ESMO Update on IO in Advanced NSCLC: Is Atezo + Bev a Potential…

Feat. S. Popat
08:05
Lung Cancer Europe (LuCE)

2020 ESMO Update on Operable NSCLC: Is There a Potential Benefit for…

Feat. S. Popat
05:56
Lung Cancer Europe (LuCE)

2020 ESMO Update on Operable NSCLC: Are Neoadjuvant Atezolizumab or …

Feat. S. Popat
19:23
Lung Cancer Europe (LuCE)

2020 ESMO Q&A on Lung Cancer: Lorlatinib in Advanced Disease, Im…

Feat. S. Popat